<DOC>
	<DOC>NCT01014585</DOC>
	<brief_summary>The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple symptoms of fibromyalgia, as demonstrated by changes in symptoms following the discontinuation of milnacipran.</brief_summary>
	<brief_title>Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Currently participating in Study MLNMD06 Receiving a stable dosage of milnacipran (50200 mg/d) at Screening/Enrollment (Visit 1) Significant risk of suicide History of mania, bipolar disorder, psychotic disorder, schizophrenia, or a current episode of major depressive disorder Myocardial infarction and/or stroke within the prior 12 months Mean systolic blood pressure &gt; 180 mm Hg or mean diastolic blood pressure &gt; 110 mm Hg at Screening (Visit 1) Active liver disease Severe renal impairment Platelet and bleeding disorders Female patients who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Milnacipran</keyword>
	<keyword>Pain</keyword>
	<keyword>Durability of Effect</keyword>
	<keyword>Loss of Therapeutic Response</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Forest Research Institute</keyword>
	<keyword>Savella Â®</keyword>
</DOC>